ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Abstract titles reveal some of ASCO’s key datasets.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.